Clinical Trial Update: Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of Pf-06650833 in rheumatoid arthritis patients with inadequate response to methotrexate; study completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• PF-06650833 (PF-06650833)

Snippet

Sponsor: Pfizer | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2020-02-27